CASC3 Antibody [FITC]
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-30321F
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
Immunohistochemistry, Immunoprecipitation
Label
FITC (Excitation = 495 nm, Emission = 519 nm)
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for CASC3 Antibody [FITC]
Immunogen
Maps to a region between residue 225 and 275 of human
cancer susceptibility candidate 3 using the numbering given in entry NP_031385.2
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for CASC3 Antibody [FITC]
Application
Recommended Usage
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunoprecipitation
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CASC3
Alternate Names
barentsz, Btz, cancer susceptibility candidate 3, Cancer susceptibility candidate gene 3 protein, metastatic lymph node 51, Metastatic lymph node gene 51 protein, MLN 51, MLN51BTZ, Protein barentsz, protein CASC3
Gene Symbol
CASC3
Additional CASC3 Products
Product Documents for CASC3 Antibody [FITC]
Product Specific Notices for CASC3 Antibody [FITC]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...